Research Article
Investigation of Genetic Polymorphisms Related to the Outcome of Radiotherapy for Prostate Cancer Patients
Table 3
Patients clinical characteristics.
| | Characteristic | No. of patients (%) |
| | Age (y), median (range) | 67.3 (52–82) | | Family history of cancer | 14 (29.2) | | Hypertension | 19 (39.6) | | Diabetes mellitus | 2 (4.2) | | Hypertension + Diabetes mellitus | 4 (8.3) | | Other Comorbidities | 6 (12.5) | | Any history of smoking | 26 (54.2) | | Gleason score | | | ≤5 | 3 (6.3) | | 6 | 25 (52.1) | | 7 | 16 (33.3) | | 8-9 | 4 (8.4) | | PSA (ng/mL) before treatment, no. of patients (PSA range) | | | ≤4 | 9 (0.63–3.80) | | 5–10 | 14 (4.13–10.00) | | 10–20 | 16 (10.60–19.50) | | >20 | 9 (21.38–151) | | PSA outcome after radiotherapy | | | PSA decreased | 37 (77.1) | | PSA did not decrease | 11 (22.9) | | Concomitant hormonal therapy | 12 (25) | | Prior surgery (prostatectomy) | 7 (14.6) | | Radiotherapy interruption | 5 (10.4) | | Total radiation dose (Gy), median (range) | 70.1 (64–74) | | Treatment duration (months), median (range) | 61.5 (49–86) | | Follow up (months), median (range) | 48 (2–92) |
|
|
Abbreviations: PSA: prostate specific antigen; Gy: Grays.
|
